August 5, 2024 4:58 am
Published by Diana Dugas
Professional Background: Univ.-Prof. Dr. Klaus Kopka (HZDR, Germany) is a radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at Technical University Dresden, Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR]. Between 2013 and 2019 he held a W3 position at Ruprecht-Karls-University of Heidelberg, Germany. At the same time he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in... Read More
August 5, 2024 12:55 am
Published by ntechmedia
Professional Background: Douglas is the Head of Research and Development at GlyTherix and leads the scientific team. He has 20 years of experience in biomedical research with a particular focus on drug development and oncology. He led the development of the Miltuximab anti-GPC-1 monoclonal antibody from preclinical studies to First in human clinical trials, and has previously been involved in the development of a novel antibody for the treatment of multiple myeloma (MDX-1097) from pre-clinical to Phase 2 clinical trials.... Read More
August 5, 2024 12:29 am
Published by ntechmedia
Professional Background: Dr. Brad Walsh is Chief Executive Officer and Managing Director of GlyTherix Ltd, a Sydney-based biotechnology company specialising in immuno-oncology. He founded GlyTherix to bring to market an innovative antibody for treatment of solid tumours from cancers such as prostate, glioblastoma, bladder, pancreas, lung, mesothelioma, ovarian and esophageal. Dr Walsh has led the company’s scientific and business development, raising capital to bring the company to successful completion of a First-in-Human safety study of Miltuximab®, its lead compound. The... Read More
August 2, 2024 6:08 am
Published by Diana Dugas
Professional: A/Prof. Benjamin Fraser is the Organic Chemistry Task Leader and a Principal Radiochemist in NST Health at the Australian Nuclear Science and Technology Organisation. After obtaining his PhD at Monash University he worked as a drug discovery scientist at Biota Holdings, followed by post-doctoral work in United States at The Scripps Research Institute. Ben collaborates with scientists across Australia and internationally on the discovery and development of new radiopharmaceuticals. Research: A/Prof. Fraser’s laboratories focus on the discovery and development... Read More
